This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Chris Martin, DPhil
CEO, Co-Founder, and Director at ADC Therapeutics

Profile

Chris Martin, DPhil, has been the Chief Executive Officer and Director of ADC Therapeutics since June 2015.

Dr. Martin played an important role in the formation of ADC Therapeutics in 2011 and has served on the company’s Board of Directors since its inception.

Previously, Dr. Martin was Co-Founder of Spirogen Ltd and its Chief Executive Officer leading up to the company’s sale to AstraZeneca in October 2013, at which point he became both a member of MedImmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Prior to the acquisition, Dr. Martin led numerous Spirogen collaboration transactions, including agreements with Genentech and Seattle Genetics.

Dr. Martin is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow.

Agenda Sessions

  • The State-of-the-Art for Optimising ADCs

    08:50